or regression was documented, the patients received a second 3-week cycle of 2 Department of Medicine, University of Califor-DDP and were then reevaluated for response. Patients with progressive disease nia-San Diego, La Jolla, California.were removed from the study. 3 Department of Pharmaceutical Sciences, Med- RESULTS.In 25 consecutive patients, the overall response rate was 20%. No reical University of South Carolina, Charleston, sponses were observed in patients treated with TAM at a dose of õ240 mg/day. South Carolina.Among 13 patients treated at or above this dose, there were 2 complete responses, 3 partial responses, 2 mixed responses, and 6 patients with progressive disease. The overall response rate for patients treated with 240 mg of TAM or higher was 38.5%. Dose-limiting toxicity, which occurred at a TAM dose of 280 mg/day, was Presented in part at the 31st Annual Meeting of primarily hematologic and gastrointestinal in nature. There was one toxic death the American Society of Clinical Oncology, Los Angeles, California, May 20-23, 1995.(due to septic neutropenia) at this dose. There were no episodes of thrombosis. CONCLUSIONS. A TAM dose of 240 mg/day is the recommended Phase II dose.Supported by Grant CA-51251 from the National Based on the 38.5% overall response rate at this dose, the authors have initiated Institutes of Health. treatment regimen, the overall response rate has been reported to those patients treated with the Dartmouth regimen with TAM com-

No abstract